Market closedNon-fractional
Apellis Pharmaceuticals/APLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Ticker
APLS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
704
Website
www.apellis.com
APLS Metrics
BasicAdvanced
$4.7B
Market cap
-
P/E ratio
-$3.45
EPS
0.87
Beta
-
Dividend rate
Price and volume
Market cap
$4.7B
Beta
0.87
Financial strength
Current ratio
3.769
Quick ratio
2.814
Long term debt to equity
38.578
Total debt to equity
40.925
Interest coverage (TTM)
-13.93%
Management effectiveness
Return on assets (TTM)
-27.90%
Return on equity (TTM)
-122.94%
Valuation
Price to revenue (TTM)
8.973
Price to book
17.73
Price to tangible book (TTM)
17.73
Price to free cash flow (TTM)
-8.536
Growth
Revenue change (TTM)
394.93%
Earnings per share change (TTM)
-45.05%
3-year revenue growth (CAGR)
27.87%
3-year earnings per share growth (CAGR)
-9.79%
What the Analysts think about APLS
Analyst Ratings
Majority rating from 18 analysts.
APLS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$172M
17.77%
Net income
-$66M
-24.97%
Profit margin
-38.53%
-36.30%
APLS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.02
-$1.17
-$0.73
-$0.54
-
Expected
-$1.32
-$0.86
-$0.69
-$0.47
-$0.32
Surprise
-22.89%
36.77%
6.36%
15.71%
-
APLS News
AllArticlesVideos
![Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fc%2Fx%2Fpress3-2533296.jpg&w=3840&q=75)
Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm
PRNewsWire·1 week ago
![Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fn%2Fk%2Fconf7-2530971.jpg&w=3840&q=75)
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
GlobeNewsWire·1 week ago
![Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fu%2Fy%2Fpress16-2514474.jpg&w=3840&q=75)
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apellis Pharmaceuticals stock?
Apellis Pharmaceuticals (APLS) has a market cap of $4.7B as of July 26, 2024.
What is the P/E ratio for Apellis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of July 26, 2024.
Does Apellis Pharmaceuticals stock pay dividends?
No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Apellis Pharmaceuticals dividend payment date?
Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Apellis Pharmaceuticals?
Apellis Pharmaceuticals (APLS) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell Apellis Pharmaceuticals stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Apellis Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.